Gastroenterology

New data show a promising machine learning tool could help specialists detect fistula risks and provide more tailored, timely care in children.

A number of systemic, industry-based and cultural factors are driving an underrepresentation of minorities in clinicals.

The features of pediatric IBD can be non-specific, but there are signs in biopsies and clinical history that may indicate what is and isn't IBD.

Major advances to biomarkers, targeted therapies and a modernized care team could help IBD specialists achieve a more nuanced care strategy for children.

New research suggests multiple antibiotic courses may influence levels of the protein zonulin—which in part may indicate a higher risk of celiac disease.

Obesity rates in the US have skyrocketed, and so has the prevalence of several comorbid gastrointestinal and hepatic diseases - not all patients know their risks or have the financial means to take preventative measures.

An interview regarding the current impacts of environmental health on food availability, nutrition, and more.

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

A new study seeks to compare the outcomes of biopsies among American children at risk of celiac disease, with European thresholds that would deem such biopsies unnecessary.

Findings from the pivotal phase 3 trial that which supported linaclotide's FDA approval show significant benefit in bowel movement and stool consistency.

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

Results showed a significant improvement in patient-reported physical well-being after 12 weeks of treatment with sofosbuvir/velpatasvir.

More than 90% of patients with CDI treated with WMT achieved clinical cure, while only 3.8% of WMTs resulted in adverse events.

Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990-2019.

Data from the VISIBLE 1 trial showed more patients receiving subcutaneous vedolizumab achieved clinical remission, mucosal healing, durable clinical response, durable clinical remission, and corticosteroid-free clinical remission compared to those receiving placebo.

Results from the systematic review and meta-analysis showed FMT restored the normal microbiome, reduced the risk of gastrointestinal infections, and did not lead to increased adverse events in patients with HIV.

Findings revealed more than 5,000 excess deaths from CDI and 35.6% excess risk compared to the expected number of disease deaths calculated using data from the National Vital Statistics System.

Nearly 95% of patients with HCV treated with DAA therapy achieved SVR, regardless of alcohol consumption.

Results from EoE KIDS showed 68% of patients on a higher dose of dupilumab and 58% of patients on a lower dose achieved significant histological disease remission.

Announced by Ionis Pharmaceuticals, topline results show olezarsen met the study's primary endpoint with a statistically significant reduction in triglyceride levels versus placebo.

Participants indicated multiple factors affected their decision to contact out-of-hours primary care for their child with gastroenteritis and detailed areas of disconnect between their expectations and actions taken by the general practitioner.

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

Results from both studies showed the safety of filgotinib for the treatment of ulcerative colitis compared to placebo treatment groups.

Nearly half of patients with IBD in remission experienced abdominal pain, which was associated with sex, fatigue, and depressive symptoms.

Although intervention increased HCV RNA testing compared to patients in the standard of care group, treatment uptake was unaffected.